MedTrace Logo

[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome

NCT05017844 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2021-08-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of KSR-001 in patients with Dry Eye Syndrome

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

KSR-001-04

One drop to both eyes four times a day for 12 weeks

DRUG

KSR-001-02

One drop to both eyes four times a day for 12 weeks

DRUG

KSR-001-03

One drop to both eyes four times a day for 12 weeks

Sponsors & Collaborators

  • Samil Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Kukje Pharma

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-18
Primary Completion
2021-02-08
Completion
2021-06-22

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05017844 on ClinicalTrials.gov